البحث عن طبيب

Mehrdad Hefazi Torghabeh, M.D.

  1. Hematologist / Oncologist

المنشورات

  1. Yacout M, Katamesh B, Jabban Y, He R, Viswanatha D, Jevremovic D, Greipp P, Bessonen K, Palmer J, Foran J, Saliba A, Hefazi-Torghabeh M, Begna K, Hogan W, Patnaik M, Shah M, Alkhateeb H, Al-Kali A. Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms. Leukemia. 2024 Dec; 38 (12):2727-2730 Epub 2024 Sept 23
    View PubMed
  2. Yadav H, Herasevich S, Zhang Z, White BA, Hefazi Torghabeh M, Hogan WJ, Schulte PJ, Niven AS, Gajic O. Pulmonary function as a continuum of risk: critical care utilization and survival after allogeneic hematopoietic stem cell transplantation - a multicenter cohort study. Bone Marrow Transplant. 2024 Jul; 59 (7):942-949 Epub 2024 Mar 16
    View PubMed
  3. Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024 Feb; 99 (2):193-202 Epub 2023 Dec 10
    View PubMed
  4. Sakemura RL, Hefazi M, Cox MJ, Siegler EL, Sinha S, Hansen MJ, Stewart CM, Feigin JM, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Forsman CL, Nevala WK, Boysen JC, Tschumper RC, Grand CL, Kuchimanchi KR, Mouritsen L, Foulks JM, Warner SL, Call TG, Parikh SA, Ding W, Kay NE, Kenderian SS. AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells. Cancer Immunol Res. 2023 Sep 01; 11(9):1222-1236.
    View PubMed
  5. Sakemura R, Cox MJ, Hefazi M, Siegler EL, Kenderian SS. Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. Leuk Lymphoma. 2021 Sep; 62(9):2052-2063. Epub 2021 Mar 08.
    View PubMed
  6. Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 Apr 1; 127 (7):1039-1048 Epub 2020 Dec 01
    View PubMed
  7. Higgins A, Khan Z, Coddington CC, Hashmi SK, Hefazi M, Alkhateeb H, Litzow MR, Hogan WJ, Cathcart-Rake E, Thompson CA, Patnaik MM. Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2019 Jun; 25 (6):1232-1239 Epub 2019 Feb 15
    View PubMed
  8. Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14; 133 (7):697-709 Epub 2018 Nov 21
    View PubMed
  9. Hefazi M, Hogan WJ, Wakefield LL, Gandhi MJ. The association of de novo anti-HLA-DPB1 donor-specific antibody formation and primary graft failure after allogeneic hematopoietic cell transplantation. Hum Immunol. 2018 Dec; 79 (12):861-864 Epub 2018 Aug 22
    View PubMed
  10. Hefazi M, Langer KJ, Khera N, Adamski J, Roy V, Winters JL, Gastineau DA, Jacob EK, Kreuter JD, Gandhi MJ, Hogan WJ, Litzow MR, Hashmi SK, Yadav H, Iyer VN, Scott JP, Wylam ME, Cartin-Ceba R, Patnaik MM. Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. Biol Blood Marrow Transplant. 2018 Sep; 24 (9):1906-1913 Epub 2018 Apr 18
    View PubMed
  11. Higgins A, Mangaonkar AA, Hefazi M, Viswanatha D, Horna P, Foran J, Gangat N. Non-internal tandem duplication (ITD), non-tyrosine kinase domain (TKD) FLT3 mutations in myeloid malignancies: A brief report of 10 patients. Leuk Res 2018 Sep; 72:1-4 Epub 2018 July 21
    View PubMed
  12. Farhadfar N, Stan MN, Shah P, Sonawane V, Hefazi MT, Murthy HS, Zou F, Sican X, Hashmi SK. Thyroid dysfunction in adult hematopoietic cell transplant survivors: risks and outcomes. Bone Marrow Transplant. 2018 Aug; 53 (8):977-982 Epub 2018 Feb 06
    View PubMed
  13. Hefazi M, Litzow MR. Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia. Blood Lymphat Cancer. 2018; 8:47-61 Epub 2018 Sept 25
    View PubMed
  14. Hefazi M, Patnaik MM, Hogan WJ, Litzow MR, Pardi DS, Khanna S. Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. Mayo Clin Proc. 2017 Nov; 92 (11):1617-1624 Epub 2017 Nov 01
    View PubMed
  15. Yalniz FF, Hefazi M, McCullough K, Litzow MR, Hogan WJ, Wolf R, Alkhateeb H, Kansagra A, Damlaj M, Patnaik MM. Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Sep; 23 (9):1478-1484 Epub 2017 May 08
    View PubMed
  16. Hefazi M, Damlaj M, Alkhateeb HB, Partain DK, Patel R, Razonable RR, Gastineau DA, Al-Kali A, Hashmi SK, Hogan WJ, Litzow MR, Patnaik MM. Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Transpl Infect Dis. 2016 Dec; 18 (6):913-920 Epub 2016 Nov 11
    View PubMed
  17. Damlaj M, Alkhateeb HB, Hefazi M, Partain DK, Hashmi S, Gastineau DA, Al-Kali A, Wolf RC, Gangat N, Litzow MR, Hogan WJ, Patnaik MM. Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Biol Blood Marrow Transplant. 2016 Aug; 22 (8):1431-1439 Epub 2016 May 07
    View PubMed
  18. Hefazi M, Litzow M, Hogan W, Gastineau D, Jacob E, Damlaj M, Hashmi S, Al-Kali A, Patnaik MM. ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning. Transfusion. 2016 Feb; 56: (2)518-27.
    View PubMed
  19. Hefazi M, Hefazi M, Siddiqui M, Patnaik M, Wolanskyj A, Wolanskyj A, Alkhateeb H, Zblewski D, Elliott M, Hogan W, Litzow M, Al-Kali A. Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. Leuk Res. 2015 Sep 3 Epub 2015 Sept 03
    View PubMed
  20. Balali-Mood M, Hefazi M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol. 2006 Oct; 99 (4):273-82
    View PubMed
  21. Hefazi M, Maleki M, Mahmoudi M, Tabatabaee A, Balali-Mood M. Delayed complications of sulfur mustard poisoning in the skin and the immune system of Iranian veterans 16-20 years after exposure. Int J Dermatol. 2006 Sep; 45 (9):1025-31
    View PubMed
  22. Etezad-Razavi M, Mahmoudi M, Hefazi M, Balali-Mood M. Delayed ocular complications of mustard gas poisoning and the relationship with respiratory and cutaneous complications. Clin Exp Ophthalmol. 2006 May-Jun; 34 (4):342-6
    View PubMed
  23. Balali-Mood M, Hefazi M, Mahmoudi M, Jalali E, Attaran D, Maleki M, Razavi ME, Zare G, Tabatabaee A, Jaafari MR. Long-term complications of sulphur mustard poisoning in severely intoxicated Iranian veterans. Fundam Clin Pharmacol. 2005 Dec; 19 (6):713-21
    View PubMed
  24. Hefazi M, Attaran D, Mahmoudi M, Balali-Mood M. Late respiratory complications of mustard gas poisoning in Iranian veterans. Inhal Toxicol. 2005 Oct; 17 (11):587-92
    View PubMed
  25. Mahmoudi M, Hefazi M, Rastin M, Balali-Mood M. Long-term hematological and immunological complications of sulfur mustard poisoning in Iranian veterans. Int Immunopharmacol. 2005 Aug; 5 (9):1479-85
    View PubMed
  26. Balali-Mood M, Hefazi M. The pharmacology, toxicology, and medical treatment of sulphur mustard poisoning. Fundam Clin Pharmacol. 2005 Jun; 19 (3):297-315
    View PubMed